FINAL TRANSCRIPT
`
`SNY - Full Year 2010 Sanofi-Aventis Earnings Conference Call
`
`Event Date/Time: Feb. 09. 2011 / 1:00PM GMT
`
`THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us
`
`©2011 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by
`framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the
`Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.
`
`Mylan Ex.1063
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`Feb. 09. 2011 / 1:00PM, SNY - Full Year 2010 Sanofi-Aventis Earnings Conference Call
`
`F I N A L T R A N S C R I P T
`
`As far as blood glucose monitoring is concerned, we believe we have good products, we have better products. We believe we
`can leverage the fact that we are the sole company which can offer insulin and needles. And yes, it's to some extent a bet, but
`first of all it's a commitment and we have to deliver.
`
`I don't share your point of view on Lixisenatide. I strongly believe that Lixisenatide is superior to Byetta. And being it's already
`just for the fact that lixi is once a day and the other product is twice a day. And against the Merck product, we have ongoing
`trials. We have to see what comes out of this. And it's premature, but yes, of course, we have the ambition to have the better
`product.
`
`Chris Viehbacher - Sanofi-Aventis - CEO
`
`And I would just add a few things. First of all, I don't think we have -- we're missing anything that Novo has. I am a little surprised
`that people can see a value in Degludec, which is essentially a me-too of Levemir, but don't want to believe the same thing
`about a Lixisenatide versus a Victoza. So somewhere I guess we've got to get a little bit better at investor relations perhaps.
`
`I think we've got a GLP-1. We've got a long-acting insulin. We've got a better position in emerging market. We'll probably be
`faster with a combo. We are slower on GLP-1 than they are, obviously. We're into blood glucose meters and they're not yet. So
`there's a huge market.
`
`Patent expiries, let's wait and see what that brings. But I don't think at this stage today that anybody really sees the patent expiry
`as being of a dramatic nature, certainly where we are. And especially when you start looking beyond the traditional markets of
`Europe and the US, we are busy switching our business in the US to the SoloSTAR. We're up to 40% conversion in the US. And
`we've still got another four or five years before we are really at that stage yet.
`
`So, at the same time, I think, as Hanspeter said, we want to see some acceleration in that business. We will be investing. And
`that's part of the reason why we also said we need to be a diabetes company. As long as we're just going to be managing a
`brand, we're not going to really be developing a diabetes business. So we've got all the elements. It now has to come together
`and it now has to be executed. And I think we would certainly accept that we have to execute better; no question about that.
`But I wouldn't say that our product lineup is not as good.
`
`Lantus is still the number-one brand in the entire diabetes world. And given everything that has happened to try to knock
`Lantus off its perch, I think actually it's shown a tremendous amount of brand loyalty and resilience.
`
`Elias? The sustained budget of Merck versus budget cutting of Pfizer. I'm interested in this one too.
`
`Dr. Elias Zerhouni - Sanofi-Aventis - President, Global R&D
`
`Put me in a tough spot here. But before I do this, I'd like to add something about the diabetes question, because I completely
`agree with what Hanspeter and Chris has said, that there's a dimension that I think people don't see why we went in this direction.
`And the dimension is this, that diabetes is only the tip of the iceberg for many other chronic conditions, chronic diseases that
`are directly related to diabetes.
`
`The comorbidities in eye disease, hence our investment in Fovea and eye, the comorbidity in the cardiovascular system, the
`renal system, and the epidemiology growth of this disease, which says that there is a need for you to look at holistically diabetes
`not from the end of product, insulin and Lixisenatide, but the end of the other part of the spectrum, a population to which you
`provide a continuum across the entire spectrum.
`
`And remember that chronic disease management is going to grow, we believe, as a part of every public health system response.
`You're not going to take care of a patient with diabetes in hospitals. So you're going to develop systems that are going to be
`
`22
`
`THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us
`
`©2011 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by
`framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the
`Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.
`
`Mylan Ex.1063
`Mylan v. Sanofi - IPR2018-01676
`
`